Young Caroline 4

What Happened Caroline Young, a director of Cumberland Pharmaceuticals, received an award (transaction code A) for 1,800 shares at an acquisition price of $2.80 per share, a total value of $5,040. The transaction is reported on a Form 4 with the reported transaction date of 2026-03-18 and the filing date of 2026-03-20. This was an award/acquisition of shares (compensation/grant), not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-03-18, 1,800 shares @ $2.80 each.
• Total reported value: $5,040.
• Filing date: Form 4 filed 2026-03-20 (filed within the typical two-business-day window).
• Shares owned after transaction: not specified in the provided filing details.
• Transaction code: "A" = award, grant or other acquisition. No footnotes or 10b5-1/withholding details were included in the provided data.

Context Awards to directors are commonly part of compensation or equity-based incentive plans and do not necessarily signal a personal purchase decision or change in sentiment. The reported value here is modest; retail investors should view this as routine director compensation unless accompanied by larger purchases or other notable insider activity.